The highly anticipated phase 3 clinical trials presented at the ESMO Congress 2023 in Madrid, Spain, could revolutionize the treatment landscape for women with gynecological cancers. The late-breaking studies, featuring groundbreaking data on managing cervical, ovarian, and endometrial cancers, offer new hope for patients by delaying relapse and extending survival.
Cervical cancer, often diagnosed as locally advanced disease in unscreened women, poses significant challenges. Standard treatment involves chemotherapy combined with radiation, as the tumor is typically too large for surgical removal. While this approach leads to remission, the cancer often resurfaces within two to three years. However, two innovative trials to be showcased at the ESMO Congress 2023 present new strategies that significantly postpone relapse, granting women more cancer-free years during their prime.
One study found that the inclusion of pembrolizumab, an immunotherapy drug, alongside standard treatment, led to a remarkable 68% of women being cancer-free after two years. Comparatively, only 57% of women in the placebo group achieved the same result. Another trial examined the impact of using induction chemotherapy, in which two different chemotherapy drugs are administered before standard treatment with chemotherapy and radiation. The results showed that women with locally advanced cervical cancer who received induction chemotherapy had a 35% higher chance of being cancer-free and a 39% higher likelihood of being alive after five years, compared to those who received conventional treatment alone. This approach holds particular promise as the drugs used in induction chemotherapy are widely available, even in low-resource countries.
Additionally, groundbreaking advancements in the treatment of cervical cancer that has metastasized or recurred after initial chemotherapy and radiation therapy will be presented. A trial focusing on the novel therapy tisotumab vedotin demonstrated extended survival, delayed relapse, and a higher occurrence of tumor shrinkage when compared to traditional chemotherapy.
In ovarian cancer, achieving remission remains a significant unmet need, with approximately 85% of patients experiencing recurrent disease and limited long-term survival after recurrence. However, the ESMO Congress 2023 will unveil randomized trial data demonstrating that a novel targeted therapy called senaparib delayed the time to relapse in patients with newly diagnosed advanced ovarian cancer.
Endometrial cancer, the most prevalent gynecological cancer in the US and Europe, will also be addressed in the trials. While a hysterectomy can cure most cases, the 15-20% of patients with more aggressive disease face limited treatment options. However, the studies to be presented at the ESMO Congress showcase significant progress. Two trials examining the addition of immunotherapy to standard chemotherapy treatment demonstrated a substantial delay in cancer relapse for women with advanced or recurrent endometrial cancer compared to chemotherapy alone.
Dr. Krishnansu Tewari, a leading expert in gynecological cancers, expects the results from the ESMO Congress 2023 to pave the way for regulatory approval of these promising new treatments. He envisions these trials as a stepping stone towards providing state-of-the-art therapies that can delay relapse, granting women struggling with gynecological cancers the opportunity to live longer, higher-quality lives.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it